ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 1736

Effectiveness and Safety of Tofacitinib vs. Calcineurin Inhibitor in Interstitial Lung Disease Secondary to Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis: A Multi-Center Cohort Study with Propensity Score-Based Inverse Probability of Treatment Weighting
Abstract Number: 1737

RheumMadness 2024: The Practical Impact of the Practically Perfect Season
Abstract Number: 1738

How Do Resident Physicians Choose a Career in Rheumatology?A Qualitative Analysis of Journey Maps
Abstract Number: 1739

Adult and Pediatric Rheumatology Fellow Education on Temporomandibular Joint (TMJ) Arthritis in Patients with Juvenile Idiopathic Arthritis
Abstract Number: 1740

Performance of Large Language Models in Rheumatology Board-Like Questions: Accuracy, Quality, and Safety
Abstract Number: 1741

Implementing Strengths-Based, Positive Approaches Within Rheumatology Fellowship Training: A Realist Evaluation of Appreciative Inquiry-Based Interventions
Abstract Number: 1742

Multi-Center Use of an Online Case-Based Simulation to Educate Pediatric Trainees on Musculoskeletal Complaints and High-Value Care
Abstract Number: 1743

What Are the Benefits of Treating Rheumatoid Arthritis Patients to Remission After Achieving Low Disease Activity in Clinical Practice?
Abstract Number: 1744

Artificial Intelligence: A Novel Tool in the Belt for Improving Rheumatoid Arthritis Outcomes in the National Health Service, United Kingdom
Abstract Number: 1745

Use of Statins and Its Association with Major Adverse Cardiovascular Outcomes with Tofacitinib versus TNF Inhibitors in a Risk-Enriched Population of Patients with Rheumatoid Arthritis
Abstract Number: 1746

Global Recruiting Patterns Are Associated with Placebo Response Rates in Clinical Trials of Rheumatoid Arthritis
Abstract Number: 1747

Native Americans Experience Profound Premature Mortality from Rheumatoid Arthritis
Abstract Number: 1748

Fracture Incidence Rates in Persons with Rheumatoid Arthritis by Disease Activity Level
Abstract Number: 1749

Safety and Long-term Efficacy of CD19-CAR T-cell Therapy in 30 Patients with Autoimmune Disease
Abstract Number: 1750

Safety and Preliminary Efficacy of CD19 CAR-T Cell Treatment in Rheumatic Disease – Data from the First Part of the Phase I/II CASTLE Basket Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].